155 related articles for article (PubMed ID: 21616917)
1. Vascular function in the diagnostic categories of polycystic ovary syndrome.
Moran LJ; Cameron JD; Strauss BJ; Teede HJ
Hum Reprod; 2011 Aug; 26(8):2192-9. PubMed ID: 21616917
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.
Toulis KA; Goulis DG; Mintziori G; Kintiraki E; Eukarpidis E; Mouratoglou SA; Pavlaki A; Stergianos S; Poulasouchidou M; Tzellos TG; Makedos A; Chourdakis M; Tarlatzis BC
Hum Reprod Update; 2011; 17(6):741-60. PubMed ID: 21628302
[TBL] [Abstract][Full Text] [Related]
4. Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome.
Brinkworth GD; Noakes M; Moran LJ; Norman R; Clifton PM
BJOG; 2006 Nov; 113(11):1308-14. PubMed ID: 17059392
[TBL] [Abstract][Full Text] [Related]
5. The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome.
Thomson RL; Brinkworth GD; Noakes M; Clifton PM; Norman RJ; Buckley JD
Hum Reprod; 2012 Jul; 27(7):2169-76. PubMed ID: 22552687
[TBL] [Abstract][Full Text] [Related]
6. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
Meyer C; McGrath BP; Teede HJ
J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
[TBL] [Abstract][Full Text] [Related]
7. Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers.
Teede H; Ng S; Hedger M; Moran L
Metabolism; 2013 Oct; 62(10):1394-400. PubMed ID: 23768911
[TBL] [Abstract][Full Text] [Related]
8. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
[TBL] [Abstract][Full Text] [Related]
9. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome.
Thomson RL; Buckley JD; Moran LJ; Noakes M; Clifton PM; Norman RJ; Brinkworth GD
BJOG; 2009 Aug; 116(9):1242-50. PubMed ID: 19438498
[TBL] [Abstract][Full Text] [Related]
10. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
11. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
12. Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype.
Armeni E; Stamatelopoulos K; Rizos D; Georgiopoulos G; Kazani M; Kazani A; Kolyviras A; Stellos K; Panoulis K; Alexandrou A; Creatsa M; Papamichael C; Lambrinoudaki I
J Hypertens; 2013 Oct; 31(10):1998-2004. PubMed ID: 24107731
[TBL] [Abstract][Full Text] [Related]
13. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.
Moran L; Teede H
Hum Reprod Update; 2009; 15(4):477-88. PubMed ID: 19279045
[TBL] [Abstract][Full Text] [Related]
14. Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin.
Fruzzetti F; Ghiadoni L; Virdis A; De Negri F; Perini D; Bucci F; Giannarelli C; Gadducci A; Taddei S
J Pediatr Adolesc Gynecol; 2016 Oct; 29(5):489-495. PubMed ID: 27018756
[TBL] [Abstract][Full Text] [Related]
15. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome.
Moran LJ; Deeks AA; Gibson-Helm ME; Teede HJ
Hum Reprod; 2012 Jul; 27(7):2082-8. PubMed ID: 22493025
[TBL] [Abstract][Full Text] [Related]
16. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome.
Choi YS; Yang HI; Cho S; Jung JA; Jeon YE; Kim HY; Seo SK; Lee BS
Steroids; 2012 Nov; 77(13):1352-8. PubMed ID: 22944040
[TBL] [Abstract][Full Text] [Related]
17. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects.
Rajendran S; Willoughby SR; Chan WP; Liberts EA; Heresztyn T; Saha M; Marber MS; Norman RJ; Horowitz JD
Atherosclerosis; 2009 Jun; 204(2):509-14. PubMed ID: 19027116
[TBL] [Abstract][Full Text] [Related]
18. Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.
Daskalopoulos G; Karkanaki A; Piouka A; Prapas N; Panidis D; Gkeleris P; Athyros VG
Curr Vasc Pharmacol; 2015; 13(6):788-800. PubMed ID: 25600030
[TBL] [Abstract][Full Text] [Related]
19. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
[TBL] [Abstract][Full Text] [Related]
20. Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome.
Soyman Z; Noyan V; Tulmac M; Yucel A; Sagsoz N; Bayrak T; Bayrak A; Cakir E
Fertil Steril; 2011 Mar; 95(3):1067-72. PubMed ID: 21193188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
